 Demetrius Lopes
Concepts (390)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 53 | 2021 | 88 | 13.880 |
Why?
| | Embolization, Therapeutic | 46 | 2021 | 80 | 13.760 |
Why?
| | Stents | 48 | 2021 | 155 | 11.410 |
Why?
| | Endovascular Procedures | 30 | 2020 | 79 | 5.320 |
Why?
| | Stroke | 29 | 2022 | 367 | 3.520 |
Why?
| | Cerebral Angiography | 34 | 2021 | 72 | 3.250 |
Why?
| | Aneurysm, Ruptured | 9 | 2020 | 27 | 3.170 |
Why?
| | Blood Vessel Prosthesis | 8 | 2020 | 27 | 3.060 |
Why?
| | Thrombectomy | 15 | 2022 | 51 | 3.020 |
Why?
| | Tomography, Optical Coherence | 7 | 2021 | 24 | 2.900 |
Why?
| | Brain Ischemia | 20 | 2022 | 122 | 2.750 |
Why?
| | Polyvinyls | 6 | 2019 | 7 | 2.570 |
Why?
| | Middle Cerebral Artery | 8 | 2019 | 22 | 2.520 |
Why?
| | Treatment Outcome | 62 | 2022 | 3910 | 2.500 |
Why?
| | Carotid Artery, Internal | 11 | 2019 | 31 | 2.470 |
Why?
| | Dimethyl Sulfoxide | 5 | 2019 | 9 | 2.040 |
Why?
| | Middle Aged | 85 | 2021 | 11209 | 2.000 |
Why?
| | Cerebrovascular Circulation | 8 | 2020 | 58 | 1.970 |
Why?
| | Humans | 130 | 2022 | 31481 | 1.960 |
Why?
| | Intracranial Arteriovenous Malformations | 3 | 2019 | 12 | 1.860 |
Why?
| | Angioplasty, Balloon | 6 | 2017 | 28 | 1.820 |
Why?
| | Male | 90 | 2020 | 17583 | 1.720 |
Why?
| | Thrombosis | 4 | 2021 | 67 | 1.570 |
Why?
| | Magnetic Resonance Angiography | 9 | 2018 | 51 | 1.560 |
Why?
| | Female | 85 | 2021 | 18253 | 1.540 |
Why?
| | Tomography, X-Ray Computed | 14 | 2018 | 891 | 1.500 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2018 | 62 | 1.490 |
Why?
| | Aged | 65 | 2021 | 10295 | 1.460 |
Why?
| | Cerebrovascular Disorders | 4 | 2019 | 123 | 1.400 |
Why?
| | Neointima | 2 | 2018 | 6 | 1.360 |
Why?
| | Adult | 51 | 2020 | 9779 | 1.350 |
Why?
| | Carotid Stenosis | 6 | 2013 | 31 | 1.340 |
Why?
| | Aneurysm | 4 | 2014 | 20 | 1.340 |
Why?
| | Arteriovenous Fistula | 2 | 2019 | 13 | 1.320 |
Why?
| | Neurosurgical Procedures | 9 | 2015 | 169 | 1.310 |
Why?
| | Carotid Artery Diseases | 6 | 2020 | 49 | 1.300 |
Why?
| | Carotid Arteries | 5 | 2020 | 57 | 1.230 |
Why?
| | Angiography, Digital Subtraction | 7 | 2018 | 12 | 1.230 |
Why?
| | Retrospective Studies | 35 | 2022 | 3591 | 1.190 |
Why?
| | Mechanical Thrombolysis | 3 | 2013 | 6 | 1.140 |
Why?
| | Cranial Sinuses | 2 | 2017 | 9 | 1.140 |
Why?
| | Aged, 80 and over | 35 | 2020 | 5234 | 1.130 |
Why?
| | Basilar Artery | 7 | 2020 | 10 | 1.110 |
Why?
| | Follow-Up Studies | 30 | 2020 | 2028 | 1.070 |
Why?
| | Models, Anatomic | 3 | 2019 | 68 | 1.020 |
Why?
| | Fibrinolytic Agents | 11 | 2017 | 99 | 0.990 |
Why?
| | Intracranial Arteriosclerosis | 5 | 2018 | 60 | 0.990 |
Why?
| | Cerebral Arteries | 5 | 2020 | 37 | 0.980 |
Why?
| | Tissue Plasminogen Activator | 9 | 2017 | 80 | 0.890 |
Why?
| | Subarachnoid Hemorrhage | 8 | 2017 | 95 | 0.880 |
Why?
| | Ultrasonography, Interventional | 2 | 2020 | 73 | 0.860 |
Why?
| | Vascular Access Devices | 6 | 2019 | 9 | 0.800 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2017 | 9 | 0.790 |
Why?
| | Paraganglioma | 1 | 2020 | 7 | 0.780 |
Why?
| | Skull Base Neoplasms | 1 | 2020 | 18 | 0.770 |
Why?
| | Printing, Three-Dimensional | 1 | 2018 | 5 | 0.720 |
Why?
| | Catheterization | 4 | 2020 | 62 | 0.710 |
Why?
| | Graft Occlusion, Vascular | 2 | 2009 | 29 | 0.700 |
Why?
| | Anterior Cerebral Artery | 2 | 2016 | 2 | 0.700 |
Why?
| | Balloon Embolectomy | 1 | 2017 | 1 | 0.680 |
Why?
| | Transverse Sinuses | 1 | 2017 | 1 | 0.680 |
Why?
| | Placenta | 1 | 2017 | 16 | 0.680 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2017 | 6 | 0.670 |
Why?
| | Dental Devices, Home Care | 1 | 2017 | 1 | 0.650 |
Why?
| | Cerebral Hemorrhage | 3 | 2016 | 141 | 0.620 |
Why?
| | Artifacts | 2 | 2014 | 35 | 0.620 |
Why?
| | Intraoperative Complications | 2 | 2014 | 76 | 0.610 |
Why?
| | Neuroprotective Agents | 1 | 2017 | 66 | 0.610 |
Why?
| | Angioplasty | 4 | 2012 | 17 | 0.600 |
Why?
| | Imaging, Three-Dimensional | 2 | 2014 | 233 | 0.580 |
Why?
| | Risk Factors | 14 | 2019 | 2664 | 0.570 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 12 | 0.560 |
Why?
| | Hematoma, Subdural, Spinal | 1 | 2015 | 4 | 0.560 |
Why?
| | Brain Edema | 1 | 2015 | 30 | 0.560 |
Why?
| | Prostheses and Implants | 2 | 2014 | 166 | 0.550 |
Why?
| | Salvage Therapy | 1 | 2015 | 42 | 0.550 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 378 | 0.550 |
Why?
| | Posterior Cerebral Artery | 1 | 2014 | 3 | 0.540 |
Why?
| | Basal Ganglia Cerebrovascular Disease | 1 | 2014 | 2 | 0.540 |
Why?
| | Angiography | 6 | 2020 | 53 | 0.530 |
Why?
| | Neuronavigation | 1 | 2014 | 9 | 0.530 |
Why?
| | Intracranial Pressure | 2 | 2013 | 24 | 0.520 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2014 | 1 | 0.520 |
Why?
| | Magnetic Resonance Imaging | 9 | 2018 | 1273 | 0.520 |
Why?
| | Carotid Artery Injuries | 1 | 2013 | 2 | 0.510 |
Why?
| | Hematoma | 1 | 2014 | 24 | 0.510 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 197 | 0.510 |
Why?
| | Embolism, Fat | 1 | 2013 | 2 | 0.510 |
Why?
| | Thromboembolism | 1 | 2014 | 37 | 0.500 |
Why?
| | Vertebral Artery Dissection | 1 | 2013 | 2 | 0.500 |
Why?
| | Fluoroscopy | 3 | 2020 | 54 | 0.500 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 121 | 0.490 |
Why?
| | Suction | 4 | 2019 | 48 | 0.490 |
Why?
| | Preoperative Care | 1 | 2014 | 146 | 0.480 |
Why?
| | Metals | 1 | 2014 | 157 | 0.480 |
Why?
| | Seizures | 1 | 2013 | 88 | 0.470 |
Why?
| | Pseudotumor Cerebri | 1 | 2012 | 6 | 0.470 |
Why?
| | Manometry | 1 | 2012 | 28 | 0.470 |
Why?
| | Brain Diseases | 1 | 2013 | 90 | 0.460 |
Why?
| | Radiography | 7 | 2013 | 717 | 0.460 |
Why?
| | Femoral Artery | 2 | 2011 | 25 | 0.450 |
Why?
| | Prospective Studies | 19 | 2021 | 1934 | 0.440 |
Why?
| | Algorithms | 1 | 2014 | 412 | 0.440 |
Why?
| | Swine | 4 | 2021 | 117 | 0.430 |
Why?
| | Aspirin | 2 | 2014 | 90 | 0.430 |
Why?
| | Severity of Illness Index | 2 | 2015 | 1240 | 0.410 |
Why?
| | Adolescent | 15 | 2020 | 2667 | 0.410 |
Why?
| | Time Factors | 10 | 2019 | 1902 | 0.400 |
Why?
| | Surgery, Computer-Assisted | 2 | 2014 | 61 | 0.400 |
Why?
| | Arteriovenous Malformations | 1 | 2010 | 3 | 0.400 |
Why?
| | Cadaver | 4 | 2020 | 356 | 0.380 |
Why?
| | Constriction, Pathologic | 5 | 2021 | 39 | 0.360 |
Why?
| | Thrombolytic Therapy | 4 | 2018 | 85 | 0.340 |
Why?
| | Vertebrobasilar Insufficiency | 2 | 2009 | 4 | 0.340 |
Why?
| | Ticlopidine | 1 | 2007 | 14 | 0.340 |
Why?
| | Young Adult | 12 | 2020 | 2277 | 0.330 |
Why?
| | Tomography Scanners, X-Ray Computed | 3 | 2017 | 12 | 0.330 |
Why?
| | Postoperative Complications | 12 | 2016 | 1083 | 0.320 |
Why?
| | Vertebral Artery | 2 | 2020 | 8 | 0.310 |
Why?
| | Ischemic Attack, Transient | 3 | 2018 | 27 | 0.310 |
Why?
| | Blood Flow Velocity | 2 | 2019 | 26 | 0.300 |
Why?
| | Magnetics | 1 | 2005 | 4 | 0.290 |
Why?
| | Prosthesis Implantation | 1 | 2005 | 43 | 0.280 |
Why?
| | Cervical Vertebrae | 3 | 2015 | 343 | 0.270 |
Why?
| | Ventriculostomy | 2 | 2017 | 11 | 0.270 |
Why?
| | Multivariate Analysis | 4 | 2019 | 390 | 0.260 |
Why?
| | Cardiac Surgical Procedures | 1 | 2005 | 98 | 0.260 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2003 | 44 | 0.250 |
Why?
| | Cerebral Infarction | 6 | 2022 | 159 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2019 | 375 | 0.250 |
Why?
| | Disease Management | 2 | 2015 | 147 | 0.240 |
Why?
| | Combined Modality Therapy | 6 | 2017 | 456 | 0.240 |
Why?
| | Animals | 6 | 2021 | 5312 | 0.230 |
Why?
| | Child, Preschool | 6 | 2020 | 786 | 0.220 |
Why?
| | Reproducibility of Results | 2 | 2020 | 886 | 0.220 |
Why?
| | Registries | 3 | 2018 | 214 | 0.210 |
Why?
| | Ligaments, Articular | 2 | 2001 | 96 | 0.210 |
Why?
| | Syndrome | 3 | 2013 | 105 | 0.210 |
Why?
| | Risk Assessment | 4 | 2015 | 806 | 0.210 |
Why?
| | Automation | 1 | 2020 | 12 | 0.200 |
Why?
| | Anatomic Landmarks | 1 | 2020 | 8 | 0.200 |
Why?
| | Microscopy | 1 | 2020 | 14 | 0.200 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 25 | 0.200 |
Why?
| | Multimodal Imaging | 1 | 2020 | 30 | 0.200 |
Why?
| | Medical Errors | 1 | 2020 | 31 | 0.200 |
Why?
| | Child | 6 | 2020 | 1572 | 0.200 |
Why?
| | Cerebral Veins | 1 | 2019 | 3 | 0.200 |
Why?
| | Coronary Artery Disease | 1 | 2002 | 159 | 0.190 |
Why?
| | Equipment Design | 5 | 2013 | 198 | 0.190 |
Why?
| | Syringes | 1 | 2019 | 12 | 0.190 |
Why?
| | Intracranial Embolism | 1 | 2019 | 5 | 0.190 |
Why?
| | Retreatment | 3 | 2019 | 18 | 0.190 |
Why?
| | Cavernous Sinus | 1 | 1998 | 1 | 0.180 |
Why?
| | Recovery of Function | 2 | 2018 | 309 | 0.180 |
Why?
| | Vasospasm, Intracranial | 2 | 2011 | 20 | 0.180 |
Why?
| | Respiratory Tract Infections | 1 | 1998 | 25 | 0.180 |
Why?
| | Infant | 4 | 2015 | 642 | 0.180 |
Why?
| | Atlanto-Axial Joint | 1 | 1998 | 19 | 0.180 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.180 |
Why?
| | Hyperglycemia | 1 | 2019 | 49 | 0.180 |
Why?
| | Feasibility Studies | 5 | 2014 | 281 | 0.180 |
Why?
| | Morbidity | 1 | 2018 | 71 | 0.180 |
Why?
| | Face | 2 | 2014 | 17 | 0.180 |
Why?
| | Joint Instability | 2 | 2001 | 374 | 0.170 |
Why?
| | Intracranial Hemorrhages | 2 | 2017 | 18 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2018 | 52 | 0.170 |
Why?
| | Nephrectomy | 2 | 2008 | 44 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2018 | 112 | 0.170 |
Why?
| | Blood Glucose | 1 | 2019 | 137 | 0.170 |
Why?
| | Injections | 1 | 2017 | 59 | 0.170 |
Why?
| | Mortality | 1 | 2018 | 99 | 0.170 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2017 | 12 | 0.170 |
Why?
| | Microsurgery | 2 | 2015 | 46 | 0.170 |
Why?
| | Equipment Failure Analysis | 3 | 2013 | 116 | 0.170 |
Why?
| | Kidney Neoplasms | 2 | 2008 | 78 | 0.160 |
Why?
| | Drug-Eluting Stents | 1 | 2017 | 13 | 0.160 |
Why?
| | Hypertension | 3 | 2017 | 283 | 0.160 |
Why?
| | Acute Disease | 4 | 2015 | 254 | 0.150 |
Why?
| | Predictive Value of Tests | 5 | 2013 | 637 | 0.150 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2017 | 115 | 0.150 |
Why?
| | Pregnancy | 1 | 2017 | 457 | 0.150 |
Why?
| | Periodicals as Topic | 1 | 2017 | 46 | 0.150 |
Why?
| | Hemodynamics | 2 | 2011 | 103 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 153 | 0.150 |
Why?
| | Computer Simulation | 1 | 2017 | 249 | 0.150 |
Why?
| | Anticoagulants | 2 | 2015 | 151 | 0.150 |
Why?
| | Cerebral Revascularization | 1 | 2015 | 1 | 0.150 |
Why?
| | Cranial Nerve Diseases | 1 | 2015 | 3 | 0.150 |
Why?
| | United States | 7 | 2018 | 2539 | 0.150 |
Why?
| | Prosthesis Design | 1 | 2018 | 511 | 0.150 |
Why?
| | Optic Nerve Diseases | 1 | 2015 | 4 | 0.140 |
Why?
| | Radiosurgery | 1 | 2015 | 43 | 0.140 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2014 | 2 | 0.140 |
Why?
| | Alloys | 1 | 2015 | 96 | 0.140 |
Why?
| | Polycystic Kidney Diseases | 1 | 2014 | 4 | 0.140 |
Why?
| | Speech Disorders | 1 | 2014 | 15 | 0.130 |
Why?
| | Lasers | 1 | 2014 | 15 | 0.130 |
Why?
| | Treatment Failure | 1 | 2015 | 187 | 0.130 |
Why?
| | Hypopituitarism | 1 | 2014 | 3 | 0.130 |
Why?
| | Disease Models, Animal | 1 | 2018 | 832 | 0.130 |
Why?
| | Pia Mater | 1 | 2014 | 7 | 0.130 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 91 | 0.130 |
Why?
| | Arachnoid | 1 | 2014 | 9 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 136 | 0.130 |
Why?
| | Balloon Occlusion | 1 | 2014 | 9 | 0.130 |
Why?
| | Arteries | 1 | 2014 | 24 | 0.130 |
Why?
| | Reoperation | 4 | 2018 | 938 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 98 | 0.120 |
Why?
| | Hypotension | 2 | 2011 | 28 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2013 | 76 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2014 | 227 | 0.120 |
Why?
| | Femoral Fractures | 1 | 2013 | 42 | 0.120 |
Why?
| | Injections, Intra-Arterial | 2 | 2011 | 15 | 0.120 |
Why?
| | Intracranial Thrombosis | 3 | 2017 | 11 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 467 | 0.110 |
Why?
| | Nicardipine | 1 | 2011 | 5 | 0.110 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2016 | 300 | 0.110 |
Why?
| | Plant Extracts | 2 | 2004 | 18 | 0.110 |
Why?
| | Perioperative Care | 1 | 2012 | 75 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2011 | 34 | 0.110 |
Why?
| | Postoperative Care | 1 | 2012 | 141 | 0.110 |
Why?
| | Decompression, Surgical | 1 | 2013 | 146 | 0.110 |
Why?
| | Radiography, Interventional | 1 | 2011 | 29 | 0.110 |
Why?
| | Transportation of Patients | 1 | 2011 | 10 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2002 | 295 | 0.110 |
Why?
| | Ultrasonography | 1 | 2012 | 210 | 0.110 |
Why?
| | Cerebral Cortex | 1 | 1993 | 206 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2011 | 91 | 0.100 |
Why?
| | Comorbidity | 2 | 2013 | 562 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2014 | 1452 | 0.090 |
Why?
| | Recurrence | 4 | 2018 | 389 | 0.090 |
Why?
| | Contrast Media | 2 | 2015 | 144 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2009 | 57 | 0.090 |
Why?
| | Neurologic Examination | 3 | 2014 | 160 | 0.090 |
Why?
| | Logistic Models | 3 | 2019 | 479 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 2008 | 46 | 0.080 |
Why?
| | Drug Resistance | 1 | 2007 | 68 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 2014 | 0.080 |
Why?
| | Cerebellar Diseases | 1 | 2007 | 11 | 0.080 |
Why?
| | Arterial Occlusive Diseases | 2 | 2014 | 21 | 0.080 |
Why?
| | Illinois | 1 | 2007 | 266 | 0.080 |
Why?
| | Equipment Failure | 2 | 2016 | 50 | 0.080 |
Why?
| | Laparoscopy | 1 | 2008 | 190 | 0.080 |
Why?
| | Brain Infarction | 1 | 2007 | 78 | 0.070 |
Why?
| | Vascular Patency | 2 | 2003 | 31 | 0.070 |
Why?
| | Administration, Intravenous | 2 | 2016 | 34 | 0.070 |
Why?
| | Circle of Willis | 2 | 2011 | 8 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 580 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2017 | 36 | 0.070 |
Why?
| | Incidence | 1 | 2007 | 829 | 0.070 |
Why?
| | Coronary Artery Bypass | 2 | 2002 | 75 | 0.070 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2004 | 5 | 0.070 |
Why?
| | Leishmania | 1 | 2004 | 1 | 0.070 |
Why?
| | Moraceae | 1 | 2004 | 1 | 0.070 |
Why?
| | Antiprotozoal Agents | 1 | 2004 | 13 | 0.070 |
Why?
| | Phytotherapy | 1 | 2004 | 17 | 0.060 |
Why?
| | Prognosis | 3 | 2015 | 1028 | 0.060 |
Why?
| | Urokinase-Type Plasminogen Activator | 2 | 2000 | 11 | 0.060 |
Why?
| | Disability Evaluation | 2 | 2017 | 332 | 0.060 |
Why?
| | Countercurrent Distribution | 1 | 2003 | 1 | 0.060 |
Why?
| | Cecropia Plant | 1 | 2003 | 1 | 0.060 |
Why?
| | Apigenin | 1 | 2003 | 1 | 0.060 |
Why?
| | Luteolin | 1 | 2003 | 1 | 0.060 |
Why?
| | Glucosides | 1 | 2003 | 3 | 0.060 |
Why?
| | Flavonoids | 1 | 2003 | 18 | 0.060 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 2004 | 52 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2004 | 187 | 0.060 |
Why?
| | Arrhythmias, Cardiac | 1 | 2004 | 158 | 0.060 |
Why?
| | Eyebrows | 1 | 2001 | 1 | 0.060 |
Why?
| | Orbit | 1 | 2001 | 3 | 0.060 |
Why?
| | Craniotomy | 1 | 2001 | 29 | 0.050 |
Why?
| | Cause of Death | 1 | 2002 | 78 | 0.050 |
Why?
| | Sphenoid Bone | 1 | 2001 | 6 | 0.050 |
Why?
| | Sarcoidosis | 1 | 2001 | 15 | 0.050 |
Why?
| | Survival Analysis | 1 | 2002 | 379 | 0.050 |
Why?
| | Sesquiterpenes | 1 | 2000 | 5 | 0.050 |
Why?
| | Bone Plates | 1 | 2001 | 57 | 0.050 |
Why?
| | Spinal Fractures | 1 | 2001 | 63 | 0.050 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2000 | 2 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2002 | 192 | 0.050 |
Why?
| | Malaria | 1 | 2000 | 6 | 0.050 |
Why?
| | Osteotomy | 1 | 2001 | 161 | 0.050 |
Why?
| | Carotid Artery, Common | 1 | 1999 | 9 | 0.050 |
Why?
| | Helminths | 1 | 1999 | 1 | 0.050 |
Why?
| | Latex | 1 | 1999 | 1 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2001 | 187 | 0.050 |
Why?
| | Anthelmintics | 1 | 1999 | 10 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2019 | 43 | 0.050 |
Why?
| | Reperfusion | 1 | 2018 | 12 | 0.050 |
Why?
| | Abducens Nerve | 1 | 1998 | 1 | 0.050 |
Why?
| | Ophthalmoplegia | 1 | 1998 | 3 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 73 | 0.050 |
Why?
| | Paresthesia | 1 | 1998 | 7 | 0.050 |
Why?
| | Collateral Circulation | 1 | 1998 | 10 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 1998 | 7 | 0.040 |
Why?
| | Paralysis | 1 | 1998 | 17 | 0.040 |
Why?
| | Pandemics | 1 | 2020 | 203 | 0.040 |
Why?
| | France | 2 | 2008 | 39 | 0.040 |
Why?
| | Patient Care Planning | 1 | 1998 | 58 | 0.040 |
Why?
| | Radioimmunoassay | 1 | 1997 | 24 | 0.040 |
Why?
| | Hypersensitivity, Immediate | 1 | 1997 | 6 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1997 | 20 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 132 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2008 | 178 | 0.040 |
Why?
| | Patient Discharge | 1 | 2019 | 163 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2017 | 37 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 2 | 2011 | 5 | 0.040 |
Why?
| | Triage | 1 | 2017 | 30 | 0.040 |
Why?
| | Head and Neck Neoplasms | 1 | 1998 | 137 | 0.040 |
Why?
| | Vascular Surgical Procedures | 2 | 2010 | 56 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2008 | 481 | 0.040 |
Why?
| | Chronic Disease | 1 | 2018 | 544 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 512 | 0.040 |
Why?
| | Inflammation | 1 | 1998 | 360 | 0.040 |
Why?
| | Mass Screening | 1 | 1997 | 199 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2015 | 61 | 0.030 |
Why?
| | Blood Coagulation Tests | 1 | 2014 | 14 | 0.030 |
Why?
| | Antidotes | 1 | 2014 | 6 | 0.030 |
Why?
| | Spinal Fusion | 1 | 2001 | 464 | 0.030 |
Why?
| | Pyridones | 1 | 2014 | 19 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2014 | 32 | 0.030 |
Why?
| | Platinum | 1 | 2013 | 6 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2013 | 16 | 0.030 |
Why?
| | Plant Leaves | 2 | 2004 | 4 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2013 | 40 | 0.030 |
Why?
| | Pyrazoles | 1 | 2014 | 55 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2013 | 19 | 0.030 |
Why?
| | Hospitalization | 1 | 2016 | 359 | 0.030 |
Why?
| | Causality | 1 | 2013 | 58 | 0.030 |
Why?
| | Device Approval | 1 | 2013 | 18 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 82 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2013 | 31 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 75 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2003 | 49 | 0.030 |
Why?
| | Pilot Projects | 1 | 2013 | 455 | 0.030 |
Why?
| | Survival Rate | 1 | 2013 | 465 | 0.030 |
Why?
| | Blood Pressure | 1 | 2011 | 260 | 0.020 |
Why?
| | Chicago | 1 | 2013 | 955 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 986 | 0.020 |
Why?
| | Polymers | 1 | 2010 | 38 | 0.020 |
Why?
| | Brain | 1 | 1999 | 1655 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2009 | 67 | 0.020 |
Why?
| | Nephrons | 1 | 2008 | 9 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2008 | 37 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 46 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 96 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2008 | 112 | 0.020 |
Why?
| | Headache | 1 | 2007 | 52 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2008 | 236 | 0.020 |
Why?
| | Databases, Factual | 1 | 2008 | 391 | 0.020 |
Why?
| | Patient Selection | 1 | 2008 | 264 | 0.020 |
Why?
| | Kidney | 1 | 2008 | 210 | 0.020 |
Why?
| | Mice | 2 | 2004 | 1894 | 0.020 |
Why?
| | Dilatation | 1 | 2005 | 13 | 0.020 |
Why?
| | Leishmaniasis | 1 | 2004 | 1 | 0.020 |
Why?
| | Triterpenes | 1 | 2004 | 3 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2004 | 10 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2003 | 43 | 0.020 |
Why?
| | Electrocardiography | 1 | 2004 | 209 | 0.010 |
Why?
| | Nervous System | 1 | 2001 | 14 | 0.010 |
Why?
| | Fracture Healing | 1 | 2001 | 41 | 0.010 |
Why?
| | Surgical Flaps | 1 | 2001 | 54 | 0.010 |
Why?
| | Dura Mater | 1 | 2001 | 21 | 0.010 |
Why?
| | Stereoisomerism | 1 | 2000 | 12 | 0.010 |
Why?
| | Atlantic Islands | 1 | 2000 | 1 | 0.010 |
Why?
| | Models, Molecular | 1 | 2000 | 99 | 0.010 |
Why?
| | Species Specificity | 1 | 2000 | 78 | 0.010 |
Why?
| | Age Distribution | 1 | 2000 | 110 | 0.010 |
Why?
| | Cysteine | 1 | 1999 | 11 | 0.010 |
Why?
| | Organotechnetium Compounds | 1 | 1999 | 9 | 0.010 |
Why?
| | Angina, Unstable | 1 | 1999 | 13 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2000 | 188 | 0.010 |
Why?
| | Bradycardia | 1 | 1999 | 29 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 1999 | 18 | 0.010 |
Why?
| | Central America | 1 | 1999 | 1 | 0.010 |
Why?
| | South America | 1 | 1999 | 5 | 0.010 |
Why?
| | Aneurysm, False | 1 | 1999 | 13 | 0.010 |
Why?
| | Radiopharmaceuticals | 1 | 1999 | 63 | 0.010 |
Why?
| | Endarterectomy, Carotid | 1 | 1999 | 12 | 0.010 |
Why?
| | Safety | 1 | 1999 | 59 | 0.010 |
Why?
| | Catheterization, Peripheral | 1 | 1999 | 18 | 0.010 |
Why?
| | Coronary Disease | 1 | 1999 | 98 | 0.010 |
Why?
| | Regression Analysis | 1 | 1999 | 319 | 0.010 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 84 | 0.010 |
Why?
| | Immunoradiometric Assay | 1 | 1997 | 3 | 0.010 |
Why?
| | Africa, Western | 1 | 1997 | 4 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 1997 | 17 | 0.010 |
Why?
| | Skin Tests | 1 | 1997 | 16 | 0.010 |
Why?
| | Allergens | 1 | 1997 | 20 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2000 | 754 | 0.010 |
Why?
|
|
Lopes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|